Medicenna to Present Updated MDNA11 Clinical Data at ESMO Immuno-Oncology Congress 2025
Key Insights
Medicenna Therapeutics (search) will present updated clinical data from the Phase 1/2 ABILITY-1 study evaluating MDNA11, a next-generation IL-2 therapy, at the ESMO Immuno-Oncology Congress in December 2025.
The presentation will cover MDNA11 as both monotherapy and in combination with pembrolizumab for advanced solid tumors (search), delivered by principal investigator Dr. André Mansinho.
MDNA11 is designed as a long-acting IL-2 Superkine with superior affinity toward CD122 (search) receptor and no CD25 (search) binding, preferentially stimulating cancer-killing effector T cells and NK cells.
Medicenna Therapeutics (search) Corp. announced that updated clinical data from its Phase 1/2 ABILITY-1 study evaluating MDNA11 will be presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025, taking place December 10-12, 2025, in London, United Kingdom.
Clinical Study Presentation Details
Dr. André Mansinho, MD MSc, Assistant Professor at the Faculty of Medicine, University of Lisbon and principal investigator of the study, will present the interim analysis on December 10, 2025. The presentation, titled "ABILITY-1, a phase 1/2 of MDNA11, a next-generation IL-2 agonist, alone or with pembrolizumab in advanced solid tumors (search): interim analysis," will showcase updated clinical data evaluating MDNA11 both as a monotherapy and in combination with pembrolizumab.
MDNA11 Mechanism and Design
MDNA11 represents an emerging best-in-class IL-2 therapy designed as a long-acting IL-2 Superkine. The drug demonstrates superior affinity toward CD122 (search) (IL-2 receptor beta) while having no CD25 (search) (IL-2 receptor alpha) binding, a design feature that enables preferential stimulation of cancer-killing effector T cells and NK cells.
Company Pipeline and Development
Medicenna Therapeutics (search) is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Beyond MDNA11, the company's pipeline includes MDNA113, a first-in-class targeted PD-1 (search) x IL-2 bispecific in development for solid tumors, designed using the company's proprietary BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and T-MASK™ (Targeted Metalloprotease Activated SuperKine) platforms.
The company also develops bizaxofusp (formerly MDNA55), an IL-4 Empowered Superkine that has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM (search), described as the most common and uniformly fatal form of brain cancer (search). Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively.
Following the conclusion of the ESMO Immuno-Oncology 2025 Congress, a copy of the presentation will be available on the "Events and Presentations" page of Medicenna's website.